Treatment of Non-Tuberculous Mycobacterial Infections With Interferon Gamma
Status:
Completed
Trial end date:
2000-11-01
Target enrollment:
Participant gender:
Summary
This is an open label study to determine the effects of the administration of
Interferon-gamma on the clinical condition and immune function of patients with severe,
treatment refractory non-tuberculosis mycobacterial infections. The study drug (interferon
gamma) will be administered subcutaneously three times a week at 0.05 mg/m(2) for one year.
We may also collect blood from the relatives of these patients and normal volunteers in order
to characterize the genetic basis, if any, of our patients' disorders.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)